Literature DB >> 9186363

Cell kinetic in epithelium and stroma of benign prostatic hyperplasia.

S Claus1, R Berges, T Senge, H Schulze.   

Abstract

The induction of benign prostatic hyperplasia (BPH) from normal prostate is obviously associated with a distinct increase in epithelial and stromal proliferation. We have shown previously that the further increase of BPH volume in aging men is not associated with a further increase in proliferation. We studied whether an imbalance between programmed cell death (apoptosis) and cell proliferation may explain continuing growth in aging men. In prostates of 17 men with BPH removed by open prostatectomy proliferating cells were localized immunohistochemically with the Ki-67 antibody. Apoptotic cells were detected with the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) method. Proliferation and apoptotic index was calculated with a computer assisted image analysis system. Mean proliferation index +/- standard deviation in epithelium (0.142 +/- 0.097) and stroma (0.121 +/- 0.082) was nearly identical. Mean apoptotic index in epithelium (0.172 +/- 0.156) was negligibly higher than the corresponding proliferation index. In stroma, however, no apoptotic cells were detectable. Proliferation index and apoptotic index in epithelium and proliferation index in stroma showed no correlation to patient age or prostate volume. In the epithelium of BPH, obviously the cell kinetic is balanced. On the other hand, our results indicate stromal growth due to cell proliferation in the absence of cell death. This may explain the continuous increase of BPH volume in aging men.

Entities:  

Mesh:

Year:  1997        PMID: 9186363     DOI: 10.1097/00005392-199707000-00074

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

Review 1.  Mesenchymal stem cells and the embryonic reawakening theory of BPH.

Authors:  W Nathaniel Brennen; John T Isaacs
Journal:  Nat Rev Urol       Date:  2018-11       Impact factor: 14.432

Review 2.  Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol).

Authors:  M Maggi; C Crescioli; A Morelli; E Colli; L Adorini
Journal:  J Endocrinol Invest       Date:  2006 Jul-Aug       Impact factor: 4.256

Review 3.  Role of prostate stem cells and treatment strategies in benign prostate hyperplasia.

Authors:  Kalyan J Gangavarapu; Peter F Jowdy; Barbara A Foster; Wendy J Huss
Journal:  Am J Clin Exp Urol       Date:  2022-06-15

4.  Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses.

Authors:  Tomoe Fujita; Yoshiaki Matsumoto; Toshimi Kimura; Shinichi Yokota; Mika Sawada; Masataka Majima; Yoshio Ohtani; Yuji Kumagai
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

Review 5.  Pharmacological effects of saw palmetto extract in the lower urinary tract.

Authors:  Mayumi Suzuki; Yoshihiko Ito; Tomomi Fujino; Masayuki Abe; Keizo Umegaki; Satomi Onoue; Hiroshi Noguchi; Shizuo Yamada
Journal:  Acta Pharmacol Sin       Date:  2009-03       Impact factor: 6.150

6.  Anti-proliferative effects of qianliening capsules on prostatic hyperplasia in vitro and in vivo.

Authors:  Xiaoyong Zhong; Jiumao Lin; Jianheng Zhou; Wei Xu; Zhenfeng Hong
Journal:  Mol Med Rep       Date:  2015-03-27       Impact factor: 2.952

7.  The Effects of Aronia melanocarpa Extract on Testosterone-Induced Benign Prostatic Hyperplasia in Rats, and Quantitative Analysis of Major Constituents Depending on Extract Conditions.

Authors:  Na-Hyun Kim; Jonghwan Jegal; Yun Na Kim; Jeong-Doo Heo; Jung-Rae Rho; Min Hye Yang; Eun Ju Jeong
Journal:  Nutrients       Date:  2020-05-28       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.